ArticleNature2023
Neutralization, effector function and immune imprinting of Omicron variants.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
33.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 172 citations in OpenAlex.
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases · 2026Trial
- Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg.Drugs in R&D · 2025Trial
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- Article
- First exposure to SARS-CoV-2 shapes IgG subclass switching after mRNA vaccination.Communications medicine · 2026Article
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- Article
- Fc-engineered antibodies enhance protection against SARS-CoV-2 lung infection and inflammation.mBio · 2026Article
- TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026Article
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
- Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes.NPJ vaccines · 2026Article
- Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.Nature microbiology · 2026Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.Cell reports · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2.NPJ vaccines · 2026Article
- Hitting the hidden: arming the immune system for the next zoonotic coronavirus spillover.The Journal of clinical investigation · 2026Article
- Exploring the diverse binding ability of SARS-CoV-2 variant RBDs to different antibody classes: a computational study.RSC advances · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses andbioRxiv : the preprint server for biology · 2026Article
- Article
- Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors at 11 institutions in 4 countries.
Amin Addetia *Department of Biochemistry, University of Washington, Seattle, WA, USA.
Luca Piccoli *Humabs BioMed, Bellinzona, Switzerland.ORCID 0000-0002-1085-6502
James Brett Case *Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0001-7331-5511
Young-Jun Park *Department of Biochemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0003-2901-6949
Martina BeltramelloHumabs BioMed, Bellinzona, Switzerland.
Barbara GuarinoHumabs BioMed, Bellinzona, Switzerland.
Ha DangVir Biotechnology, San Francisco, CA, USA.
Guilherme Dias de MeloInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.ORCID 0000-0003-0747-7760
Dora PintoHumabs BioMed, Bellinzona, Switzerland.
Kaitlin SprouseDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0003-0007-2226
Suzanne M ScheafferDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Jessica BassiHumabs BioMed, Bellinzona, Switzerland.ORCID 0000-0002-4723-6892
Chiara Silacci-FregniHumabs BioMed, Bellinzona, Switzerland.
Francesco MuoioHumabs BioMed, Bellinzona, Switzerland.ORCID 0000-0003-4963-8665
Marco DiniHumabs BioMed, Bellinzona, Switzerland.ORCID 0009-0003-4251-5176
Lucia VincenzettiHumabs BioMed, Bellinzona, Switzerland.
Rima AcostaVir Biotechnology, San Francisco, CA, USA.
Daisy JohnsonVir Biotechnology, San Francisco, CA, USA.
Sambhavi SubramanianVir Biotechnology, San Francisco, CA, USA.
Christian SalibaHumabs BioMed, Bellinzona, Switzerland.ORCID 0000-0003-0100-6976
Martina GiurdanellaHumabs BioMed, Bellinzona, Switzerland.
Gloria LombardoHumabs BioMed, Bellinzona, Switzerland.
Giada LeoniHumabs BioMed, Bellinzona, Switzerland.
Katja CulapHumabs BioMed, Bellinzona, Switzerland.ORCID 0000-0002-0956-0018
Carley McAlisterVir Biotechnology, San Francisco, CA, USA.
Anushka RajeshVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-7729-0865
Exequiel DellotaVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-2006-3880
Jiayi ZhouVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-4231-3422
Nisar FarhatVir Biotechnology, San Francisco, CA, USA.
Dana BohanVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-9239-3053
Julia NoackVir Biotechnology, San Francisco, CA, USA.
Alex ChenVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0003-2620-5066
Florian A LemppVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0001-6103-8078
Joel QuispeDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Lauriane KergoatInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.ORCID 0000-0002-5609-4398
Florence LarrousInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.ORCID 0000-0003-0881-4263
Elisabetta CameroniHumabs BioMed, Bellinzona, Switzerland.
Bradley WhitenerDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Olivier GianniniFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.ORCID 0000-0003-2306-0498
Pietro CippàFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Alessandro CeschiFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.ORCID 0000-0002-4308-0405
Paolo FerrariFaculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.ORCID 0000-0002-9619-3104
Alessandra Franzetti-PellandaClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Maira BiggiogeroClinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.
Christian GarzoniClinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Stephanie ZappiDivision of Nephrology, Cantonal Hospital Aarau, Aarau, Switzerland.
Luca BernasconiInstitute of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland.
Min Jeong KimDivision of Nephrology, Cantonal Hospital Aarau, Aarau, Switzerland.
Laura E RosenVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-8030-0219
Gretja SchnellVir Biotechnology, San Francisco, CA, USA.
Nadine CzudnochowskiVir Biotechnology, San Francisco, CA, USA.
Fabio BenigniHumabs BioMed, Bellinzona, Switzerland.
Nicholas FrankoDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.ORCID 0000-0001-8165-6332
Jennifer K LogueDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.ORCID 0000-0002-7889-8960
Courtney YoshiyamaDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Cameron StewartDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-2786-6256
Helen ChuDivision of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.ORCID 0000-0001-8502-9600
Hervé BourhyInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, Paris, France.ORCID 0000-0002-2608-5589
Michael A SchmidHumabs BioMed, Bellinzona, Switzerland.ORCID 0000-0002-1137-9322
Lisa A PurcellVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0002-9565-2030
Gyorgy SnellVir Biotechnology, San Francisco, CA, USA.ORCID 0000-0003-1475-659X
Antonio LanzavecchiaHumabs BioMed, Bellinzona, Switzerland.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA. mdiamond@wustl.edu.ORCID 0000-0002-8791-3165
Davide CortiHumabs BioMed, Bellinzona, Switzerland. dcorti@vir.bio.ORCID 0000-0002-5797-1364
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.ORCID 0000-0002-6019-8675
VIR Biotechnology (United States) · USUniversity of Washington · USInstitut Pasteur · FRClinica Luganese Moncucco · CHEnte Ospedaliero Cantonale · CHKantonsspital Aarau · CHWashington University in St. Louis · USHoward Hughes Medical Institute · USSt. Andrews University · USUNSW Sydney · AUVir Biotechnology (Switzerland) · CH
Funding
Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7MTRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0MStructure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI Francois J Villinger · 2022 to 2026
$15.3MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MTraining in Cellular & Molecular BiologyT32GM136534 · NIGMS · UNIVERSITY OF WASHINGTON · PI Andrew Atwell Oberst, LARRY S ZWEIFEL · 2021 to 2026
$5.8MUnraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MNIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966NIAID NIH HHS R01 AI157155NIGMS NIH HHS T32 GM007270NIGMS NIH HHS T32 GM136534
Abstract
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain
Indexed as
Antibodies, NeutralizingCOVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCOVID-19 VaccinesCricetinaeCross ReactionsHumansImmune EvasionMembrane FusionMemory B CellsMiceMutationACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingCOVID-19 VaccinesS309 antibodysotrovimabSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.